These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 24842595

  • 1. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P.
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [Abstract] [Full Text] [Related]

  • 2. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 3. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
    Qu GP, Shi M, Wang D, Wu JH, Wang P, Gong ML, Zhang ZJ.
    BMC Pulm Med; 2021 Jul 01; 21(1):208. PubMed ID: 34210314
    [Abstract] [Full Text] [Related]

  • 4. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 5. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y.
    Mol Cancer Ther; 2016 Dec 01; 15(12):3040-3054. PubMed ID: 27612490
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    PLoS One; 2013 Dec 01; 8(3):e59708. PubMed ID: 23527257
    [Abstract] [Full Text] [Related]

  • 7. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 8. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH, Wang LF, Cao F, Fan FT, Xu ZY.
    Zhonghua Zhong Liu Za Zhi; 2013 Oct 01; 35(10):732-6. PubMed ID: 24378092
    [Abstract] [Full Text] [Related]

  • 9. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
    Lee TG, Jeong EH, Kim SY, Kim HR, Kim CH.
    Int J Cancer; 2015 Jun 01; 136(11):2717-29. PubMed ID: 25382705
    [Abstract] [Full Text] [Related]

  • 10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 11. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T.
    Clin Cancer Res; 2010 Nov 15; 16(22):5489-98. PubMed ID: 21062933
    [Abstract] [Full Text] [Related]

  • 12. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 15; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 13. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.
    Lung Cancer; 2013 Sep 15; 81(3):354-361. PubMed ID: 23769318
    [Abstract] [Full Text] [Related]

  • 14. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 15; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 15. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T, Ohba M, Arata S, Ohmori T.
    J Vis Exp; 2017 Aug 11; (126):. PubMed ID: 28829429
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 17. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
    Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC.
    Br J Cancer; 2008 Sep 16; 99(6):911-22. PubMed ID: 19238632
    [Abstract] [Full Text] [Related]

  • 18. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W.
    Proc Natl Acad Sci U S A; 2007 Dec 26; 104(52):20932-7. PubMed ID: 18093943
    [Abstract] [Full Text] [Related]

  • 19. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
    Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.
    Mol Cancer Ther; 2008 Apr 26; 7(4):874-9. PubMed ID: 18413800
    [Abstract] [Full Text] [Related]

  • 20. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S.
    J Thorac Oncol; 2014 Jun 26; 9(6):775-83. PubMed ID: 24828661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.